PHERGain-2, a phase II study of chemotherapy de-escalation using a pathological response-guided strategy in patients with HER2-positive, low-risk early breast cancer, is now approved in 5 new countries this month!
The results of the PHERGain trial paved the way for PHERGain-2 which is assessing the viability of the chemotherapy free alternative PHESGO™ - a combination of trastuzumab and pertuzumab – for the treatment of HER2+ early breast cancer.
We will have sites in Spain, Italy, Germany, Hungary and Bulgaria.
The recruitment is currently open in Spain and 51 patients are already benefiting from the trial treatment, with 5 patients who have had surgery and 4 who have achieved complete pathological response.
Currently, our top recruitment is at Hospital Universitari Dexeus (Dra. Garrigós) and Hospital Virgen del Rocio (Dr. Ruiz) in Spain. We want to thank all the investigators in Spain for their continuous interest!
The first sites in Italy and Germany will be at Azienda Ospedaliero-Universitaria di Parma with Dr. Musolino, and Kliniken Essen Mitte with Dr. Kümmel. Finally, opening sites in these 5 countries will give the chance to 393 patients to enroll in the study. We are very happy to extend this innovative trial to our neighboring European countries.
If you want more information about the trial in general, please do not hesitate to contact us!